Beijing Aosaikang Pharmaceutical's (SHE:002755) said the liareitinib tablets were included in China's National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance list, according to a Shenzhen bourse filing on Monday.
The drug is used to treat patients with non-small cell lung cancer.
The catalog will be effective Jan. 1, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments